US 11275092

Here's a concise summary of US Patent 11275092:

US Patent 11275092

• Title: Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
• Assignee: Quanterix Corp
• Inventors: David Wilson, John Henrik Zetterberg, Kaj Blennow, Jeffrey D. Randall
• Filing Date: July 25, 2019 (for application US16/522,237, which led to this patent)
• Issue Date: March 15, 2022
• Abstract: The patent describes methods for determining a treatment plan and/or predicting a patient's recovery from a brain injury. In some cases, the brain injury is caused by a lack of oxygen (hypoxic event). The methods involve measuring the concentration of tau protein in a patient sample, such as blood, that is suspected of containing this protein.

Plain-Language Overview of Independent Claims:

The patent contains several independent claims, each outlining a method for determining a treatment protocol and/or prognosis for a patient's recovery from a brain injury, particularly those resulting from a hypoxic event, by measuring tau protein levels.

• Independent Claim 1: This claim describes a method for determining a treatment plan and/or prognosis for a patient's recovery from a brain injury. It involves taking a blood sample (or plasma/serum from it), performing a highly sensitive assay to measure the concentration of tau protein, and then using this measured concentration to decide the prognosis or treatment. The assay must be sensitive enough to detect tau protein at a limit of detection less than about 0.2 pg/mL, and the measured tau concentration is typically less than about 5 pg/mL.
• Independent Claim 6: This claim focuses on a method for providing data to assist in determining a treatment protocol and/or prognosis. It involves performing a high-sensitivity assay on a blood sample (or plasma/serum) to measure tau protein, where the assay has a limit of detection less than about 0.2 pg/mL. The data from this measurement is then provided to enable the determination of the patient's prognosis or treatment based on the tau protein concentration.
• Independent Claim 13: This claim outlines a method for determining a treatment protocol and/or prognosis by analyzing multiple samples over time. It requires measuring tau protein concentration in a series of samples taken from the patient after the brain injury, where the measurements are performed using an assay with a limit of detection less than about 0.2 pg/mL, and the concentration of tau protein is less than about 5 pg/mL. The prognosis or treatment is then determined based on these measured concentrations.
• Independent Claim 17: This claim also describes a method for determining a treatment protocol and/or prognosis, specifically by looking at the change in tau protein levels over time. It involves taking multiple samples over at least 48 hours, performing an assay with a limit of detection less than about 0.2 pg/mL to determine tau concentration (which is less than about 5 pg/mL), and then calculating the "area under the curve" from a graph of tau protein concentration versus time. This area can be for the entire sampling period or specifically for a "second peak" in tau concentration. The prognosis or treatment is then determined based on this calculated area under the curve.

Litigation Information (as of April 26, 2026):

US Patent 11275092 is currently active. Publicly available information indicates the following:

• A PTAB case, IPR2025-01060, has been filed but was "Not Instituted - Procedural."
• A litigation case has been filed in the Delaware District Court (case number 1:25-cv-00659).